Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Semaglutide non-response usually traces to dose timing, eating compensation, plateau, sleep or alcohol, clinical factors, or biological variation in response
• For compounded semaglutide specifically, formulation and dose-accuracy questions add a layer worth verifying
• STEP 1 documented 14.9% mean weight loss at semaglutide 2.4 mg over 68 weeks; about 14% of participants lost under 5%
• Plateau on semaglutide typically appears around week 28-40, earlier than tirzepatide plateau
• Switching to tirzepatide is a reasonable consideration after addressing other factors at maximum semaglutide doses

Direct answer

Semaglutide may not produce weight loss for several reasons: you may still be in titration at sub-therapeutic doses; your eating may be matching the reduced appetite; you may have reached the expected plateau around week 28-40; sleep, alcohol, or clinical factors may be interfering; or you may be in the biological modest-responder subset. For compounded semaglutide specifically, formulation quality and dose accuracy add additional considerations worth verifying.

Table of contents

1. The semaglutide product landscape: brand vs compounded
2. Dose timing and titration
3. The week 28-40 plateau pattern
4. Eating compensation patterns
5. The sleep-alcohol-stress factors
6. Compounded semaglutide quality verification
7. Clinical conditions that blunt response
8. The biological modest-responder subset
9. When to switch to tirzepatide
10. The contrary view: accepting a modest result
11. FAQ
12. Sources

The semaglutide product landscape: brand vs compounded

Semaglutide is available in several forms, each with different dosing and clinical context:

• Wegovy (subcutaneous semaglutide, 2.4 mg weekly maximum): FDA-approved for chronic weight management; the primary trial-backed weight loss formulation
• Ozempic (subcutaneous semaglutide, 0.25-2 mg weekly): FDA-approved for type 2 diabetes; off-label weight loss use is common but at lower max dose than Wegovy
• Rybelsus (oral semaglutide, 7-14 mg daily): FDA-approved for type 2 diabetes; modest weight effects compared to injectable
• Compounded semaglutide (variable dose, prepared by 503A pharmacies for individual patients with documented clinical reasons): not FDA-approved

If you're on Ozempic for weight loss and at 0.5 mg or 1 mg, you're at a sub-therapeutic dose for weight goals. The full weight-loss dose is in Wegovy at 2.4 mg. Compounded semaglutide is often prescribed at doses matching the Wegovy range.

Dose timing and titration

Semaglutide titration moves through standard steps:

Weeks	Standard Dose	Weight effect
1-4	0.25 mg	Tolerability; minimal weight effect
5-8	0.5 mg	Light therapeutic; modest weight loss
9-12	1.0 mg	Building therapeutic effect
13-16	1.7 mg	Strong therapeutic; meaningful loss
17+	2.4 mg (Wegovy max)	Full therapeutic; STEP 1 study dose

Patients at lower doses than 1.7 mg may not see the weight effects associated with the maintenance phase. Titration can extend if tolerability requires.

The week 28-40 plateau pattern

STEP 1 weight trajectory showed:

• Weeks 1-16: Acceleration through titration
• Weeks 17-28: Peak rate of loss
• Weeks 29-40: Slowing as plateau approaches
• Weeks 41-68: Plateau; minimal additional loss

Stalled progress at week 32 is often normal slowing, not true plateau. True plateau (no progress for 8+ weeks at full therapeutic dose) typically appears around week 40-50.

Eating compensation patterns

Reduced appetite doesn't automatically equal reduced calorie intake. Common compensation:

• Calorie-dense small meals (nuts, cheese, oils)
• Liquid calories (smoothies, juices, sweetened drinks, alcohol)
• Grazing throughout the day
• Eating without checking hunger
• Weekend reversal of weekday eating
• Inadequate protein leading to muscle loss and metabolic rate reduction

A 3-day food log including a weekend often reveals patterns the patient hadn't tracked.

The sleep-alcohol-stress factors

Sleep under 7 hours raises hunger hormones, lowers satiety signals, increases cortisol, and reduces insulin sensitivity. Tasali et al. (JAMA Internal Medicine, March 2022) documented a 270 calorie/day intake increase tied to sleep restriction.

Chronic stress promotes visceral fat through cortisol elevation and drives emotional eating that can override appetite suppression.

Alcohol (7 cal/g) doesn't engage satiety mechanisms. Three drinks weekly adds 450-1200 calories; seven drinks adds 1000-2800.

Addressing these factors is often higher-leverage than dose escalation.

Compounded semaglutide quality verification

For compounded semaglutide specifically, dose accuracy and product quality are worth verifying if response is below expectation. The relevant questions:

• Is the pharmacy licensed 503A? Verify through state pharmacy board license database.
• Is USP 797 compliance documented? Legitimate pharmacies can describe their sterile compounding program.
• Is the API from an FDA-registered supplier? Chain of custody documentation should exist.
• Is third-party potency testing performed? Best-practice pharmacies test finished product through independent labs.
• What is the product concentration? Concentration affects how much volume you inject for a given mg dose. Calibration errors can produce under- or over-dosing.

If the source can't answer these questions or evades them, the source quality is suspect. Non-licensed sources (research-chemical websites, gray-market vendors, sources without verifiable pharmacy partnership) are not legitimate and may be the actual cause of "non-response."

If you're confident the source is legitimate but still not progressing, work through the standard causes (eating, sleep, alcohol, clinical factors) before assuming the compounded product is the issue.

Clinical conditions that blunt response

Conditions worth screening:

• Hypothyroidism (TSH, free T4)
• PCOS in women (clinical history, hormonal labs)
• Insulin resistance (HbA1c, fasting insulin)
• Medications promoting weight gain (SSRIs, atypical antipsychotics, beta-blockers, corticosteroids)
• Cushing's syndrome (rare)
• Perimenopause/menopause

Identification and treatment of an underlying condition often make availables weight loss progress that semaglutide alone could not produce.

The biological modest-responder subset

STEP 1 distribution:

• ~14% lost under 5% body weight
• ~32% lost 5-15%
• ~32% lost 15-20%
• ~22% lost 20%+

Biological variation in GLP-1 receptor signaling, insulin sensitivity, gut microbiome composition, and other factors contributes to where individuals fall on this distribution. The modest-responder subset is real and is not necessarily about adherence or effort.

When to switch to tirzepatide

Transition is reasonable when:

• You've been on semaglutide 2.4 mg (or equivalent compounded dose) for 12+ weeks with inadequate progress
• You've addressed the other levers
• You tolerate semaglutide but it isn't producing the result
• Tirzepatide cost and access are workable

SURMOUNT-1 documented higher mean weight loss with tirzepatide 15 mg (22.5% over 72 weeks) than STEP 1 with semaglutide 2.4 mg (14.9% over 68 weeks). For semaglutide modest responders, tirzepatide can produce additional progress.

The contrary view: accepting a modest result

A reasonable position: weight loss medication has limits. If you've achieved 10-15% weight loss on semaglutide and reached a stable plateau, the medication has done substantive work. Pushing further may produce diminishing returns at significant cost (side effect burden, financial cost, time).

For these patients, the question shifts to:

• Maintenance at current weight (often the realistic goal)
• Continued therapy for cardiovascular protection (SELECT trial documented 20% reduction in major adverse cardiovascular events with semaglutide)
• Quality-of-life improvements from existing weight loss
• Future consideration of stronger options if available

This is a legitimate conversation to have with your prescriber. Not every "non-response" requires switching or escalating.

Decision framework

Early in therapy: Patience through titration.

At therapeutic dose with limited progress: Work through the standard causes; verify compounded quality if applicable.

Persistent limited progress despite addressing causes: Consider clinical workup or transition to tirzepatide.

Reached stable plateau in modest range: Discuss maintenance vs alternative strategies.

What to verify before using this answer

The useful next step for Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this safety and medication use page, the most relevant search terms are why, not, losing, weight, semaglutide. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Why am I not losing weight on semaglutide?
Six common causes: dose timing, eating compensation, plateau, sleep/alcohol, clinical factors, modest-responder biology.

Is compounded as effective as brand?
Same molecule; trial data applies to brand; compounded quality affects real-world result.

Could my compounded semaglutide be under-dosed?
Possible at non-licensed sources; licensed 503A with quality testing is generally accurate.

What dose is needed for weight loss?
2.4 mg weekly is the FDA-approved Wegovy maximum; compounded prescriptions often match this range.

How long until weight loss?
Initial loss within 4-6 weeks; substantial loss requires titration to therapeutic doses.

Should I increase my dose?
Discuss with prescriber; 2.4 mg is the ceiling for brand.

Why did I lose then stop?
Biological plateau pattern around week 28-40.

Could my response be biologically modest?
Yes; about 14% of STEP 1 participants lost under 5%.

Should I switch to tirzepatide?
Reasonable consideration after addressing other factors at max semaglutide dose.

What if compounded isn't working?
Verify pharmacy quality; consider transition to brand or tirzepatide if persistent.

Sources

1. Wilding JPH et al., STEP 1, NEJM March 2021
2. Rubino D et al., STEP 4, JAMA April 2021
3. Lincoff AM et al., SELECT, NEJM November 2023
4. Wegovy FDA prescribing information
5. Ozempic FDA prescribing information
6. Jastreboff AM et al., SURMOUNT-1, NEJM July 2022
7. Tasali E et al., JAMA Internal Medicine March 2022
8. USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations
9. Federal Food, Drug, and Cosmetic Act Section 503A
10. Endocrine Society Clinical Practice Guideline on Obesity, 2023
11. American Thyroid Association screening guidelines
12. National Sleep Foundation duration recommendations

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians for GLP-1 therapy. This article is educational. Individual situations require clinical assessment by your prescriber.

Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP, STEP 4, and SELECT trial data apply to brand Wegovy and Ozempic specifically.

Results Disclaimer. Individual outcomes vary substantially. STEP 1 reported a 14.9% mean weight loss with significant variation; ~14% of participants lost under 5%. Your result depends on dose, adherence, baseline, lifestyle, and physiology.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent.